637 results on '"Vignetti, M."'
Search Results
152. The role of autotransplantation in chronic lymphocytic leukemia and results from the italian group
153. The role of autotrasplantation in chronic lymphocytic leucemia and results from the italian group
154. The role of autotransplantation in chronic lymphocytic leukemia and results from the italian group
155. Second malignancy after treatment of adult acute myeloid leukemia. Cohort study on adult patients enrolled in GIMEMA trials
156. Treatment of elderly patients with acute promyelocytic leukemia. The GIMEMA experience
157. MRD1/P-gp, MRP1 and LRP expression: frequency and prognostic role in adult acute lymphoblastic leukemia patients uniformly treated according to the GIMEMA 0496 protocol
158. MRD1/P-gp expression predicts achievement of remission in adult acute lymphoblastic leukemia patients
159. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
160. MDR1 expression predicts achievement of remission in adult acute lymphoblastic leukemia patients uniformely treated according to the GIMEMA 0496 protocol
161. Liposomal daunorubicin plus cytosine arabinoside for elder patients with acute myeloid leukemia. The Gimema experience
162. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine
163. Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene
164. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine
165. The Unconventional Di Bella Cancer Treatment. A Reflection on the Italian Experience
166. Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy
167. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).
168. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
169. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes
170. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
171. Trapianto di cellule staminale emopoietiche (T-CSE) in età evolutiva: quanti e dove in Italia
172. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
173. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study
174. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells
175. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission
176. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
177. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.
178. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children
179. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
180. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
181. The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL)
182. 208 Iron chelation therapy with deferasirox in transfusion dependent myelodysplastic syndrome patients. Preliminary report from the prospective MDS0306 GIMEMA trial
183. 322 TET2 mutations, methylation profile and prognosis in higher risk myelodysplastic syndromes (MDS) treated with 5-azacytidine and valproic acid
184. 147 Involvement in treatment decisions, desire for prognostic information and quality of life in high-risk myelodysplastic syndromes: the physician's perspective
185. FATAL PNEUMONIA IN CHILDREN AFTER BONE MARROW TRANSPLANTATION. REPORT FROM THE ITALIAN REGISTRY
186. Clinical studies with Interleukin-2 in patients with Acute Myelogenous Leukemia in different phases of Disease
187. AUTOLOGOUS BMT AND ACUTE LYMPHOBLASTIC LEUKEMIA IN 2nd OR SUBSEQUENT REMISSION: DATA FROM THE AIEOP (ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY-ONCOLOGY
188. Treatment approach in heavely pretreated ALL adults in first BM relapse
189. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
190. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party
191. The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience
192. Evaluation of short- and long-term response to treatment in GIMEMA protocol for Acute Myeloid Leukaemia
193. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR–ABL1-positive acute lymphoblastic leukemia patients
194. Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
195. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method
196. Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?
197. OP08 High dose (HD-AraC) vs standard dose cytosine arabinoside (SD-AraC) during induction in acute myelogenous leukemia (AML): Impact on stem cell mobilization after consolidation and on autologous transplantation (AML-12 trial)
198. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial
199. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61 70 years: results of the prospective EORTC GIMEMA AML 13 study
200. High Levels of Tumor Load Reduction after Intensive Chemotherapy Favorably Affect the Prognosis of BCR/ABL+ ALL Adult Patients Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.